Comparison of plasma biomarkers and amyloid PET for predicting memory decline in cognitively unimpaired individuals.

Autor: Jack CR Jr; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA., Wiste HJ; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA., Algeciras-Schimnich A; Department of Laboratory Medicine, Mayo Clinic, Rochester, Minnesota, USA., Weigand SD; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA., Figdore DJ; Department of Laboratory Medicine, Mayo Clinic, Rochester, Minnesota, USA., Lowe VJ; Department of Nuclear Medicine, Mayo Clinic, Rochester, Minnesota, USA., Vemuri P; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA., Graff-Radford J; Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA., Ramanan VK; Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA., Knopman DS; Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA., Mielke MM; Department of Epidemiology and Prevention, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA., Machulda MM; Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota, USA., Fields J; Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota, USA., Schwarz CG; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA., Cogswell PM; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA., Senjem ML; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA., Therneau TM; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA., Petersen RC; Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Jazyk: angličtina
Zdroj: Alzheimer's & dementia : the journal of the Alzheimer's Association [Alzheimers Dement] 2024 Mar; Vol. 20 (3), pp. 2143-2154. Date of Electronic Publication: 2024 Jan 24.
DOI: 10.1002/alz.13651
Abstrakt: Background: We compared the ability of several plasma biomarkers versus amyloid positron emission tomography (PET) to predict rates of memory decline among cognitively unimpaired individuals.
Methods: We studied 645 Mayo Clinic Study of Aging participants. Predictor variables were age, sex, education, apolipoprotein E (APOE) ε4 genotype, amyloid PET, and plasma amyloid beta (Aβ)42/40, phosphorylated tau (p-tau)181, neurofilament light (NfL), glial fibrillary acidic protein (GFAP), and p-tau217. The outcome was a change in a memory composite measure.
Results: All plasma biomarkers, except NfL, were associated with mean memory decline in models with individual biomarkers. However, amyloid PET and plasma p-tau217, along with age, were key variables independently associated with mean memory decline in models combining all predictors. Confidence intervals were narrow for estimates of population mean prediction, but person-level prediction intervals were wide.
Discussion: Plasma p-tau217 and amyloid PET provide useful information about predicting rates of future cognitive decline in cognitively unimpaired individuals at the population mean level, but not at the individual person level.
(© 2024 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.)
Databáze: MEDLINE
Externí odkaz: